scholarly journals Enhanced anti-PD-1 therapy in hepatocellular carcinoma by tumor vascular disruption and normalization dependent on combretastatin A4 nanoparticles and DC101

Theranostics ◽  
2021 ◽  
Vol 11 (12) ◽  
pp. 5955-5969
Author(s):  
Xin Bao ◽  
Na Shen ◽  
Yan Lou ◽  
Haiyang Yu ◽  
Yue Wang ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Vascular Disruption ◽  
Combretastatin A4

pH-sensitive pullulan-based nanoparticle carrier of methotrexate and combretastatin A4 for the combination therapy against hepatocellular carcinoma

Biomaterials ◽  
2013 ◽  
Vol 34 (29) ◽  
pp. 7181-7190 ◽  
Author(s):  
Yinsong Wang ◽  
Hongli Chen ◽  
Yuanyuan Liu ◽  
Jing Wu ◽  
Ping Zhou ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Combination Therapy ◽  
Ph Sensitive ◽  
Combretastatin A4

Imaging approaches to assess mechanism-of-action and response in patients with advanced hepatocellular carcinoma treated with the novel oncolytic poxvirus JX-594.

2013 ◽  
Vol 31 (4_suppl) ◽  
pp. 210-210
Author(s):  
Richard H. Patt ◽  
David H. Kirn ◽  
Caroline Breitbach ◽  
James M. Burke ◽  
Riccardo Lencioni
Keyword(s):  
Hepatocellular Carcinoma ◽  
Oncolytic Virus ◽  
Advanced Hepatocellular Carcinoma ◽  
The Novel ◽  
Mri Imaging ◽  
Vascular Disruption ◽  
Imaging Results ◽  
Anti Cancer ◽  
Mri Scans ◽  
Tumor Measurements

210 Background: The novel oncolytic virus JX-595 has demonstrated anti-cancer mechanisms of action, as defined in preclinical models, which includes cytolysis, intra-tumoral vascular disruption, and immune-mediated tumor targeting. Methods: To determine whether mechanism(s) of action (MOA) of the novel anti-cancer oncolytic virus JX-594 could be demonstrated by MRI imaging in patients with advanced hepatocellular carcinoma (HCC), dynamic contrast-enhanced MRI of the liver was performed at baseline, day 5, and week 8 following intra-tumoral injection. Images were evaluated by a central reviewer blinded to treatment and dose using both modified RECIST and Choi response criteria. 17/30 subjects underwent day 5 (D5) post-treatment imaging; 28/30 had week 8 (W8) imaging. Results: Choi responses correlated more reliably than RECIST with JX-594 MOA. Evidence of intra-tumoral vascular shutdown, manifest by areas of reduced or non-enhancement (Choi response), was observed in 6 of 17 subjects on D5 5 MRI scans. Day 5 Choi responses were a predictor of week 8 Choi responses in all but 1 subject. Of the 11/17 D5 Choi non-responders, 3 were Choi responders at 8 weeks. Increase in size at D5 of small lesions present at baseline (“unmasking”) is compatible with oncolytic flare due to intra-tumoral edema contributed to by cell lysis and immune infiltration. RECIST criteria tumor measurements did not identify MOA of JX-594, and resulted in the appearance of pseudoprogression at D5 in some subjects. Conclusions: Hyperacute MRI post-therapy can be used to detect activity of the JX-594, a novel oncolytic anti-cancer therapy. Day 5 Choi responses were a predictor of subsequent response at week 8. Clinical trial information: NCT00554372.

Photoacoustic microscopy for evaluating combretastatin A4 phosphate induced vascular disruption in orthotopic glioma

2018 ◽  
Vol 11 (10) ◽  
pp. e201700327 ◽  
Author(s):  
Renzhe Bi ◽  
Ghayathri Balasundaram ◽  
Seungwan Jeon ◽  
Hui Chien Tay ◽  
Yang Pu ◽  
...  
Keyword(s):  
Photoacoustic Microscopy ◽  
Vascular Disruption ◽  
Combretastatin A4 ◽  
Orthotopic Glioma

scholarly journals Front Cover: Photoacoustic microscopy for evaluating combretastatin A4 phosphate induced vascular disruption in orthotopic glioma (J. Biophotonics 10/2018)

2018 ◽  
Vol 11 (10) ◽  
pp. e201870161
Author(s):  
Renzhe Bi ◽  
Ghayathri Balasundaram ◽  
Seungwan Jeon ◽  
Hui Chien Tay ◽  
Yang Pu ◽  
...  
Keyword(s):  
Photoacoustic Microscopy ◽  
Front Cover ◽  
Vascular Disruption ◽  
Combretastatin A4 ◽  
Orthotopic Glioma

scholarly journals Co-administration of combretastatin A4 nanoparticles and anti-PD-L1 for synergistic therapy of hepatocellular carcinoma

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Bonan Zhao ◽  
Zhipeng Dong ◽  
Weixing Liu ◽  
Fangning Lou ◽  
Qiyan Wang ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Primary Liver Cancer ◽  
Tumor Therapy ◽  
Hepatic Tumor ◽  
Combination Group ◽  
Tumor Site ◽  
Liver Malignancies ◽  
Hypoxic Conditions ◽  
Tumor Tissues ◽  
Combretastatin A4

Abstract Background According to data estimated by the WHO, primary liver cancer is currently the fourth most common malignant tumor and the second leading cause of death around the world. Hepatocellular carcinoma (HCC) is one of the most common primary liver malignancies, so effective therapy is highly desired for HCC. Results In this study, the use of poly(l-Aspartic acid)-poly(ethylene glycol)/combretastatin A4 (CA4-NPs) was aimed to significantly disrupt new blood vessels in tumor tissues for targeted hepatic tumor therapy. Here, PEG-b-PAsp-g-CA4 showed significantly prolonged retention in plasma and tumor tissue. Most importantly, CA4-NPs were mainly distributed at the tumor site because of the triple target effects—enhanced permeability and retention (EPR) effect, acid-sensitive (pH = 5.5) effect to the tumor microenvironment (TME), and good selectivity of CA4 for central tumor blood vessel. Considering that CA4-NPs might induce severe hypoxic conditions resulting in high expression of HIF-1α in tumor tissues, which could induce the overexpression of PD-L1, herein we also used a programmed death-ligand 1 antibody (aPD-L1) to prevent immunosuppression. This way of complementary combination is able to achieve an ideal treatment effect in tumor site where CA4-NPs and aPD-L1 could respond to the inner area and peripheral area, respectively. As a result, a significant decrease in tumor volume and weight was observed in the combination group of CA4-NPs plus aPD-L1 compared with CA4-NPs or aPD-L1 monotherapy in subcutaneous Hepa1-6 hepatic tumor models. Conclusions We presented a new idea that co-administration of CA4-NPs and aPD-L1 possessed notable anti-tumor efficacy for HCC treatment. Graphic abstract

Co-Administration of Combretastatin A4 Nanoparticles and Sorafenib for Systemic Therapy of Hepatocellular Carcinoma

2019 ◽  
Author(s):  
Yalin Wang ◽  
Haiyang Yu ◽  
Dawei Zhang ◽  
Guanyi Wang ◽  
Wantong Song ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Systemic Therapy ◽  
Combretastatin A4

Co-administration of combretastatin A4 nanoparticles and sorafenib for systemic therapy of hepatocellular carcinoma

2019 ◽  
Vol 92 ◽  
pp. 229-240 ◽  
Author(s):  
Yalin Wang ◽  
Haiyang Yu ◽  
Dawei Zhang ◽  
Guanyi Wang ◽  
Wantong Song ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Systemic Therapy ◽  
Combretastatin A4

Multimodality treatment of hepatocellular carcinoma

1998 ◽  
Vol 13 (11-s4) ◽  
pp. S315-S319 ◽  
Author(s):  
ZHAO-YOU TANG ◽  
XIN-DA ZHOU ◽  
ZENG-CHEN MA ◽  
ZHI-QUAN WU ◽  
JIA FAN ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Multimodality Treatment
Sign in / Sign up

Export Citation Format

Share Document